Tumor Treating Fields (Optune)
Treatment for Brain And Central Nervous System Cancer
Typical Dosage: Continuous wear of transducer arrays >18 hours/day
Effectiveness
65%
Safety Score
70%
Clinical Trials
7
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Continuous wear of transducer arrays >18 hours/day
Time to Effect
3-6 months
Treatment Duration
lifetime / until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
13(Treat 13 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$250,000
Monitoring:$5,000
Side Effect Mgmt:$1,000
Total Annual:$256,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$500,000/QALY
QALYs Gained
0.25
Comparison vs Temozolomide
Cost Difference
+$220,000/year
More expensive
QALY Difference
+0.25 QALYs
Better outcomes
Dominance
No dominance
Tumor Treating Fields (Optune) Outcomes
for Brain And Central Nervous System Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Remission Rate
+1%
Common Side Effects
Skin irritation/rash
+45%
Headache
+15%
Fatigue
+15%
Sources:
Active Clinical Trials
4 active trials recruiting for Tumor Treating Fields (Optune) in Brain And Central Nervous System Cancer
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
NCT03223103ACTIVE NOT RECRUITINGPHASE1
13 participants
INTERVENTIONAL
The Bronx, United States
Started: Mar 1, 2018
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
NCT03033992ACTIVE NOT RECRUITINGNA
80 participants
INTERVENTIONAL
Phoenix, United States +10 more
Started: Apr 4, 2017
WBSI Guided Personalized Delivery of TTFields
NCT05086497RECRUITINGNA
155 participants
INTERVENTIONAL
Philadelphia, United States +1 more
Started: Jan 15, 2023
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
NCT03194971RECRUITING
20 participants
OBSERVATIONAL
Milwaukee, United States
Started: Jun 1, 2017
Completed Clinical Trials
2 completed trials for Tumor Treating Fields (Optune) in Brain And Central Nervous System Cancer
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NCT00916409COMPLETEDPHASE3
700 participants
INTERVENTIONAL
Birmingham, United States +88 more
Started: Jun 1, 2009
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
NCT02903069COMPLETEDPHASE1
66 participants
INTERVENTIONAL
La Jolla, United States +7 more
Started: Aug 17, 2016